San Francisco startup Framework Therapeutics is also focusing on an oral, at the time-each day GLP-one drug identified as GSBR-1290—the drug surpassed Wall Road’s expectations in June any time a mid-phase examine showed ordinary weight loss of about six% and it strategies to begin another mid-phase demo toward the tip of the yr—that founder a